DANIELLE LEÃO

Dr. DANIELLE LEÃO

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
TSTayse Silva dos Santos
Tayse Silva dos Santos
RTRenato Sampaio Tavares
Renato Sampaio Tavares
DLDANIELLE LEÃO
DANIELLE LEÃO
Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.

20 December 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
EBElizabeth Budde
Elizabeth Budde
HZHuilai Zhang
Huilai Zhang
WKWon Seog Kim
Won Seog Kim
DMDai Maruyama
Dai Maruyama
EREduardo Rego
Eduardo Rego
JWJason Westin
Jason Westin
PURPOSE: Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy. METHODS: In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point. RESULTS: A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in <5% of patients and patient-reported outcomes were improved compared with R-GemOx. CONCLUSION: Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.

1 July 2020 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
VHVania Hungria
Vania Hungria
Marcia GarnicaMarcia Garnica
Marcia Garnica
ECEdvan Crusoe
Edvan Crusoe
RFRoberto Jose Pessoa de Magalhaes Filho
Roberto Jose Pessoa de Magalhaes Filho
GMGracia Martinez
Gracia Martinez
AMAngelo Maiolino
Angelo Maiolino
Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in different intensities during their treatment. Most of them are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.

1 January 2020 in Hematology
Verified
Journal Article
Open access
CCCarlos Chiattone
Carlos Chiattone
DGDavid Gomez-Almaguer
David Gomez-Almaguer
CPCarolina Pavlovsky
Carolina Pavlovsky
ETElena J. Tuna-Aguilar
Elena J. Tuna-Aguilar
ABAna L. Basquiera
Ana L. Basquiera
PBPaula Barreyro
Paula Barreyro
To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America.This chart review study (NCT02559583; 2008–2015)evaluated time to progression (TTP) and overa...

14 November 2025 in Blood Advances
Verified
Journal Article
Open access
Andrew SpencerAndrew Spencer
Andrew Spencer
MGMaria Gavriatopoulou
Maria Gavriatopoulou
DCDaniel Coriu
Daniel Coriu
ALAnna Lysén
Anna Lysén
Norma C. GutiérrezNorma C. Gutiérrez
Norma C. Gutiérrez
CHCarlos Hader
Carlos Hader
Genetic abnormalities in multiple myeloma (MM) influence treatment outcomes and may inform therapeutic decisions. The most common chromosomal translocation in MM is t(11;14); however, its role in disease progression is not well defined. We report results from MEDICI, a global, minimally invasive, prospective study evaluating t(11;14) status in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM). MEDICI enrolled adult patients (≥18 years) with MM with bone marrow (BM) aspirates collected at diagnosis and/or disease relapse. The primary objective was to determine t(11;14) prevalence in patient BM samples using fluorescent in situ hybridization (FISH) with plasma cell enrichment. Samples from 525 patients (NDMM, n = 306; RRMM, n = 219) were analyzed for t(11;14), with 498 patients (95%) having successful BM FISH test. Prevalence of t(11;14) was 22.1% (110/498 patients; 95% confidence interval [CI], 18.5-26.0) in the overall patient population, 18.8% (56/298 patients; 95% CI, 14.5-23.7) in NDMM, and 27.0% (54/200 patients; 95% CI, 21.0-33.7) in RRMM. Patients with t(11;14)-positive MM were evenly distributed across disease stages (stage I, 24.1%; stage II, 20%; stage III, 21.3%); however, higher rates were observed in African American patients (RRMM odds ratio [OR], 7.27, 95% CI, 1.33-39.83; P = .022) and light-chain only disease (NDMM OR, 3.02, 95% CI, 1.33-6.87; P = .008). Chromosome 1q abnormalities occurred more often in the absence of t(11;14); however, higher frequency of mutation in the plasma cell differentiation regulator IRF4 was detected in t(11;14) presence. In conclusion, the results from MEDICI demonstrated reproducible t(11;14) detection with a real-world prevalence of 22.1% in MM. This trial was registered at www.ClinicalTrials.gov as #NCT04721002.

18 July 2025 in Blood Global Hematology
Verified
Journal Article
Open access
VPVerena Pfister
Verena Pfister
FMFernanda de Morais Marques
Fernanda de Morais Marques
TSTalita Silveira
Talita Silveira
JFJayr Schmidt Filho
Jayr Schmidt Filho
VMVinicius Campos de Molla
Vinicius Campos de Molla
CACelso Arrais-Rodrigues
Celso Arrais-Rodrigues